Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;21(10):2192-2202.
doi: 10.1111/dom.13811. Epub 2019 Jun 30.

Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol

Ronald M Goldenberg  1 , Jeremy D Gilbert  2 , Irene M Hramiak  3 , Vincent C Woo  4 , Bernard Zinman  5
Affiliations
Review

Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol

Ronald M Goldenberg et al. Diabetes Obes Metab. 2019 Oct.

Abstract

Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a risk mitigation strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.

Keywords: SGLT inhibitors; diabetic ketoacidosis; type 1 diabetes.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon). 2018;47:22-27.
    1. Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetologia. 2019;62:408-417.
    1. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels: International Diabetes Federation; 2017.
    1. Foster NC, Beck RW, Miller KM, et al; for the T1D Exchange Clinic NetworkState of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21:66-72.
    1. Foster NC, Miller K, Dimeglio L, et al. Marked increases in CGM use has not prevented increases in HbA1c levels in participants in the T1D Exchange (T1DX) Clinic Network. Diabetes. Orlando, FL: 78th Scientific Sessions of the American Diabetes Association; 2018:1689.

MeSH terms